10 years of Jackson Lab science shows the lifesaving power of genome-matched cancer treatment | Opinion

Maine’s Genomics Initiative Brings Precision Cancer Care to Rural Hospitals

By Maine News Now

In a state where medical centers are separated by winding roads and wide stretches of forest, a decade‑long project has turned Maine into a national example of how advanced genomic testing can be made accessible to rural patients. The Maine Cancer Genomics Initiative (MCGI), launched in 2012, was created to give doctors statewide the tools to interpret cancer genomes and to connect patients with targeted therapies that improve survival.

The Spark

Edison T. Liu, MD, the former president of The Jackson Laboratory (JAX) in Bar Harbor, began his career as a cancer physician. “I asked myself every day, ‘How can I use my findings to better treat my cancer patients?’” Liu told Maine News Now. He noted that while biomedical discovery had exploded, many clinicians—especially those in rural areas—were left struggling to make sense of increasingly complex genomic reports.

“It was not the rate of discovery that was the problem,” Liu explained. “It was the difficulty that talented medical practitioners have in understanding and deploying powerful, but complex, technologies to benefit their patients.”

When Liu arrived at JAX in 2012, he and Chuck Hewett, the lab’s executive vice president and a fellow Mainer, decided that the state’s physicians could not be left behind. Together they envisioned a program that would bring cutting‑edge testing directly into Maine hospitals and provide a forum for interpreting the results.

The Birth of MCGI

The plan was funded with an $8.4 million gift from the Harold Alfond Foundation and set up a collaborative structure that leveraged JAX’s expertise and the clinical knowledge of local oncologists. Bangor physician Jens Rueter, MD, became the project’s leading clinical partner.

Under MCGI, patients who enroll in the cohort study receive tumor sequencing through JAX. The lab then runs computational analyses that match mutations to possible therapeutic options. The results are presented in a statewide genomic tumor board where Maine physicians present their most challenging cases to a panel that includes JAX scientists and experts from across the country. The board’s recommendations become the basis for personalized treatment plans.

Impact on Patients and Providers

According to MCGI records, more than 1,600 Maine cancer patients have been enrolled in the cohort study, and the program has touched the lives of over 4,000 patients and their families in the last decade. Patients who received targeted therapies suggested by the board “survived longer with their cancer,” Liu said, citing improved outcomes reported in internal studies.

Doctors, too, have seen tangible benefits. “The participating physicians reported increased self‑confidence in interpreting and using genomic reports, which previously seemed confusing,” Liu noted. Surveys of Maine oncologists show that the program has reduced uncertainty in treatment decisions and has enabled the use of therapies that were previously unavailable to rural patients.

National Recognition

In 2022, the National Cancer Institute selected Dr. Rueter and the MCGI team to lead a national 18‑institution trial testing whether a genomic tumor board can increase the use of targeted therapeutics across all cancers. The trial is a testament to Maine’s success in “implementation science”—the discipline of designing system‑wide approaches to disseminate complex technologies for better health outcomes.

“Thus, our small rural state became a national leader in implementation sciences,” Liu reflected. The initiative has demonstrated that advanced genomic technologies can be effectively distributed and applied even in geographically dispersed, low‑density settings.

Looking Forward

The MCGI team is expanding its services. New partnerships with genetic counselors are underway to help patients navigate hereditary cancer risks. The laboratory is also streamlining the tumor board process to reduce turnaround times and deepen the mutational analysis. Outreach to additional hospital systems across the state aims to broaden access to precision oncology.

“We are engaging genetic counselors to help patients navigate any underlying genetic susceptibility to cancer,” Liu said. “We have dramatically improved the efficiency of the genomic tumor boards, as well as the depth of the mutational analysis. We are expanding outreach to other hospital systems.”

The Takeaway

The Maine Cancer Genomics Initiative is a story about community, collaboration, and the power of small, focused efforts. “Small is mighty,” Liu summed up, a phrase that echoes across the initiative’s achievements. For a state that is defined by its size and geography, the project shows that with the right partnerships and investment, patients in rural areas can receive the same level of precision care afforded to those in large urban centers.

As Maine celebrates the decade of MCGI, the initiative’s continued growth promises to keep the state at the forefront of bringing cutting‑edge science to the bedside.